11 May 2020
Wales-based Hybrisan has secured £0.5m equity backing to help become a major force in the global war against harmful bacteria and viruses such as COVID-19.
The Port Talbot company’s team of experienced commercially focused scientists has introduced its WT range of biocide and antimicrobial solutions at a time of huge demand worldwide for products to kill and control the spread of harmful pathogens.
Cardiff based access to finance company Severn Seed Finance (SSF) advised the company on the successful raise, which has been provided by a syndicate of local South Wales “Business Angels” under SSF’s investment umbrella, alongside funding from the Development Bank for Wales.
David Maas, Founder of SSF said ““We specialise in raising risk investment and Hybrisan’s experienced team of commercially focussed scientists and innovative products were a winning combination. Hybrisan has genuinely exciting biocide technology specifically developed to control the spread of harmful bacteria and viruses such as COVID-19, and effectively manage the impact bacteria has on industrial and commercial processes. The emergence of COVID-19 and other viruses has spotlighted the urgent demand for new solutions to global and industry wide infection and contamination issues.”
Dr. Chris Mortimer, Hybrisan’s Technical Director said ““We are delighted to have secured this investment at a critical stage in worldwide demand for innovative solutions to infection. This investment is vital to complete development of our next generation of anti-bacterial products which are capable of revolutionising the way harmful bacteria is managed in a wide range of filtration solutions, and in applications ranging from aviation to medical PPE and wound dressings.”
David Maas said SSF had initially advised the Hybrisan Team on its strategic investment options via the Welsh Government’s Accelerated Growth Programme before moving to the funding stage. “Our network of “Angel investors” can bring finance plus work and life experiences to the table, which, for an early stage business, is a winning combination.”
Dr. Lee Bridgeman Co-Founder of Hybrisan said “We quickly recognised SSF’s capabilities and David Maas’s depth of knowledge and experience in raising early stage funding. David’s commitment, belief and expertise throughout the funding process was invaluable, as well as his input on the how to maximise the full potential of our business in future.”
More information on Severn Seed Finance Ltd. visit https://www.severnseedfinance.com/ or contact from David Maas email@example.com
More information about Hybrisan Ltd. visit https://www.hybrisan.com/ or Dr. Chris Mortimer firstname.lastname@example.org